provided to 52.0%, which is also sufficient. The percentage of carbohydrate in the diet was increased in 2 times. From micronutrients in the diet of patients was revealed lack of calcium, phosphorus, and also expressed a lack of iodine, zinc, selenium, folic acid, vitamin A, vitamin E, thiamine, Niacin. Of the required amount of 40.8 g. dietary fiber patients received a total of 8.8 grams. The value of protein in the actual nutrition of patients conforms to the standards but significantly exceeded the recommended value of FAO/WHO. ConClusions: Thus, in the actual nutrition of patients in the Oncology hospitals the energy value of the ration of dietary intake, intake of total proteins, fats, carbohydrates was low than the approved standard. Especially pronounced was the lack of dietary fiber, micronutrients. In the hospitals of Kazakhstan it is necessary to apply the methods of correction of the protein component of the diet using a composite of mixtures with a high biological value and a set of essential nutrients. PCN314 BRCA1/

No abstract

Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia among the elderly people in Western societies. CLL is genetically and molecularly heterogeneous disease that translates into clinical outcomes. Currently, the most unfavorable prognosis is associated with the presence of deletion of the short arm of chromosome 17 (del17p) and/or mutation of the TP53 gene (mTP53) that requires an individualized therapeutic approach. Allogenic hematopoietic stem cells transplantation (allo-HSCT) is still the only potentially curative treatment option in patients with CLL. Nevertheless, it is associated with high toxicity and treatment-related mortality. Therefore, it can be used only in selected patients, mostly young and fit without significant comorbidities. Moreover, allo-HSCT should be performed in patients who achieve disease remission. Recent advances in molecular biology have led to the better understanding of CLL pathophysiology and development of new targeted therapies. Recently developed and approved drugs such as new anti-CD20 monoclonal antibodies (obinutuzumab, ofatumumab), B-cell receptor inhibitors (BCRi) (ibrutinib, idelalisib) and B-cell lymphoma 2 (BCL-2) protein inhibitor (venetoclax) provide better clinical outcomes in CLL patients than previously used standard chemotherapy regimens. Most of those new drugs have been included in treatment algorithms described in Polish, European and global clinical practice guidelines. However, not all of them are available for Polish patients due to the lack of reimbursement, leaving them in the clinical unmet need state. This review summarizes recent advances in CLL treatment, focusing on the Polish perspective.